Eledon Pharmaceuticals (ELDN) Non-Current Deferred Tax Liability (2020 - 2026)

Eledon Pharmaceuticals' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Non-Current Deferred Tax Liability changed 0.18% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed 0.18% YoY) and the FY2025 annual result came in at $2.2 million, changed 0.18% from the prior year.
• Non-Current Deferred Tax Liability was $2.2 million for Q1 2026 at Eledon Pharmaceuticals, roughly flat from $2.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.2 million in Q4 2025 and bottomed at $1.8 million in Q1 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability slumped 51.4% — and 2024, when it advanced 24.6%.
• Eledon Pharmaceuticals' Non-Current Deferred Tax Liability stood at $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then grew by 24.6% to $2.2 million in 2024, then gained by 0.18% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• Business Quant data shows ELDN's Non-Current Deferred Tax Liability at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $2.2 million in Q3 2025.